Haddad et al. assessed the use of Herceptin (trastuzumab) on 14 patients with salivary gland tumors (SGC), three of which had MECa tumors with overexpressed HER2/neu in their salivary gland tumors. This evidence concerns the gene ERBB2 and tumor of salivary gland.